Regcon is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $14.4B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Regcon's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Eliquis | Bristol Myers Squibb / Pfizer | Generic | 2028 | FDA-approved, Sep 2020 | $14.4B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Regcon's share of it.